secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0000950170-24-028647
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data
--------------------------------------------------------------------------------

- Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.
- Raised ~$320.2M net in March 2024 underwritten offering to fund clinical pipeline.
- Phase 1 JANX007 in mCRPC: 83% PSA50 at first step dose ≥0.2mg; no CRS > Grade 2.
- Phase 1 JANX008: NSCLC subject achieved RECIST PR with 100% target lesion reduction, no CRS.
- Co-founder Dr. Tommy DiRaimondo promoted to CSO; JANX007 update expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/0000950170-24-028647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024028647/janx-20240308.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-028647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer